Novel Non-opioid Pain Management Medications Under Development
Semnur Pharmaceuticals, Inc. is a biopharmaceutical company focused on the clinical and commercial development of innovative products that meet the needs of pain management practitioners and their patients.
Back pain affects most adults, causes disability for some, and is a common reason for seeking healthcare. In the United States, opioid prescription for low back pain has increased, and opioids are now the most commonly prescribed drug class. More than half of regular opioid users report back pain. Rates of opioid prescribing in the US and Canada are two to three times higher than in most European countries.
Semnur’s lead program, SP-102 (SEMDEXA™), is the first non-opioid novel injectable corticosteroid gel formulation for patients with moderate to severe chronic radicular pain/sciatica, containing no preservatives, surfactants, solvents, or particulates. If approved by the FDA, SP-102 (SEMDEXA™) will be available in a pre-filled syringe formulation and will be administered as an epidural injection for the treatment of sciatica.
In the United States, Semnur Pharmaceuticals plans to develop and commercialize product candidates, either through its own efforts or in conjunction with partners. Outside of the United States, we anticipate commercializing these products through select regional partnerships worldwide.
Our primary focus lies in the development of non-opioid products for meeting the needs of underserved patients with back pain. We believe that the therapeutic advantages of our product and technology will improve products’ efficacy and safety making a substantial improvement in the treatment of back pain.
* NIH, National Institute of Arthritis and Musculoskeletal and skin diseases (n.d.). Back Pain: MedlinePlus.
** CDC, HCUP, Semnur data on file.
